What's Happening?
Mosaic Therapeutics, a clinical-stage oncology therapeutics company, is set to present preclinical data for its lead program, MOS101, at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, California. The presentation
will focus on the combination of the MDM2 antagonist ASTX295 and olaparib, a PARP inhibitor, as a novel treatment for BRCA2 mutant, TP53 wild-type solid tumors. This development follows Mosaic's in-licensing of ASTX295 and ASTX029 from Astex Pharmaceuticals in April 2025. The company is finalizing plans for a Phase 1b/2a study to evaluate this combination therapy in patients with biomarker-selected solid tumors.
Why It's Important?
The presentation of MOS101's preclinical data is significant as it highlights a potential new treatment option for cancers with limited targeted therapies. The combination of ASTX295 and olaparib could offer a novel approach to treating BRCA2 mutant, TP53 wild-type solid tumors, addressing a substantial unmet need in oncology. This development underscores Mosaic Therapeutics' commitment to advancing precision oncology through innovative combination therapies. The success of this program could have a considerable impact on the oncology therapeutics market, potentially benefiting patients with specific genetic profiles who currently have few treatment options.
What's Next?
Mosaic Therapeutics plans to commence a Phase 1b/2a clinical study in early 2027 to further evaluate the efficacy and safety of the ASTX295 and olaparib combination. The outcome of this study will be crucial in determining the future clinical development and potential commercialization of this therapy. Stakeholders, including patients, healthcare providers, and investors, will be closely monitoring the results, which could influence future research directions and investment in precision oncology.
